Arcutis Biotherapeutics (ARQT) Return on Capital Employed (2020 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Return on Capital Employed of 1.13% for Q1 2026, up 4864.0% year-over-year from 0.02% in Q1 2025, and up 125.24% quarter-over-quarter from 4.49% in Q4 2025.
Arcutis Biotherapeutics (ARQT) Return on Capital Employed (2020 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 1.13% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4864.0% year-over-year to 1.13%; the TTM figure through Mar 2026 stood at 1.13% (up 4864.0% YoY), while the FY2025 annual figure was 4.68%, up 4393.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 1.13%, up from 4.49% in the prior quarter.
- The five-year high for Return on Capital Employed was 1.13% in Q1 2026, with the low at 100.89% in Q2 2023.
- The 5-year median for Return on Capital Employed is 65.99% (2022), against an average of 57.42%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed slumped 4995 bps in 2022, then jumped 5707 bps in 2024.
- Arcutis Biotherapeutics' Return on Capital Employed stood at 68.35% in 2022, then tumbled by 30 bps to 89.13% in 2023, then soared by 54 bps to 41.14% in 2024, then soared by 89 bps to 4.49% in 2025, then soared by 125 bps to 1.13% in 2026.
- Business Quant data shows ARQT's Return on Capital Employed at 1.13% in Q1 2026, 4.49% in Q4 2025, and 14.6% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 10.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.91% |
| Mar 31, 2026 | 1.13% |
| Dec 31, 2025 | -4.49% |
| Sep 30, 2025 | -14.60% |
| Jun 30, 2025 | -35.13% |
| Mar 31, 2025 | -47.50% |
| Dec 31, 2024 | -41.14% |
| Sep 30, 2024 | -67.73% |
| Jun 30, 2024 | -43.81% |
| Mar 31, 2024 | -54.17% |
| Dec 31, 2023 | -89.13% |
| Sep 30, 2023 | -93.74% |
| Jun 30, 2023 | -100.89% |
| Mar 31, 2023 | -83.55% |
| Dec 31, 2022 | -68.35% |
| Sep 30, 2022 | -82.83% |
| Jun 30, 2022 | -84.26% |
| Mar 31, 2022 | -65.99% |
| Dec 31, 2021 | -56.70% |
| Sep 30, 2021 | -43.31% |